Pathogenesis, Clinical Manifestations, and Natural History of Diabetic Nephropathy

Comprehensive Clinical Nephrology: Fourth Edition

Volumn , Issue , 2010, Pages 359-376

  Ritz, Eberhard ^a   Wolf, Gunter ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84874116732     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-323-05876-6.00029-0     Document Type: Chapter

References (65)

1. Seaquist ER, Goetz FC, Rich S, Barbosa J Familial clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathy. N Engl J Med 1989, 320:1161-1165.
2. Nelson RG, Knowler WC, Pettitt DJ, et al. Diabetic kidney disease in Pima Indians. Diabetes Care 1993, 16:335-341.
3. Nelson RG, Morgenstern H, Bennett PH Intrauterine diabetes exposure and the risk of renal disease in diabetic Pima Indians. Diabetes 1998, 47:1489-1493.
4. Amri K, Freund N, Van Huyen JP, et al. Altered nephrogenesis due to maternal diabetes is associated with increased expression of IGF-II/mannose-6-phosphate receptor in the fetal kidney. Diabetes 2001, 50:1069-1075.
5. Zandi-Nejad K, Luyckx VA, Brenner BM Adult hypertension and kidney disease: The role of fetal programming. Hypertension 2006, 47:502-508.
6. Janssen B, Hohenadel D, Brinkkoetter P, et al. Carnosine as a protective factor in diabetic nephropathy: Association with a leucine repeat of the carnosinase gene CNDP1. Diabetes 2005, 54:2320-2327.
7. Marre M, Jeunemaitre X, Gallois Y, et al. Contribution of genetic polymorphism in the renin-angiotensin system to the development of renal complications in insulin-dependent diabetes: Genetique de la Nephropathie Diabetique (GENEDIAB) study group. J Clin Invest 1997, 99:1585-1595.
8. Ruggenenti P, Bettinaglio P, Pinares F, Remuzzi G Angiotensin converting enzyme insertion/deletion polymorphism and renoprotection in diabetic and nondiabetic nephropathies. Clin J Am Soc Nephrol 2008, 3:1511-1525.
9. Schmidt S, Ritz E Angiotensin I converting enzyme gene polymorphism and diabetic nephropathy in type II diabetes. Nephrol Dial Transplant 1997, 12(Suppl 2):37-41.
10. Satriano J, Vallon V Primary kidney growth and its consequences at the onset of diabetes mellitus. Amino Acids 2006, 31:1-9.
11. Ruster C, Wolf G The role of chemokines and chemokine receptors in diabetic nephropathy. Front Biosci 2008, 13:944-955.
12. Wolf G, Ziyadeh FN Cellular and molecular mechanisms of proteinuria in diabetic nephropathy. Nephron Physiol 2007, 106:26-31.
13. Mezzano S, Aros C, Droguett A, et al. NF-κB activation and overexpression of regulated genes in human diabetic nephropathy. Nephrol Dial Transplant 2004, 19:2505-2512.
14. Isermann B, Vinnikov IA, Madhusudhan T, et al. Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis. Nat Med 2007, 13:1349-1358.
15. Simonson MS Phenotypic transitions and fibrosis in diabetic nephropathy. Kidney Int 2007, 71:846-854.
16. Gilbert RE, Marsden PA Activated protein C and diabetic nephropathy. N Engl J Med 2008, 358:1628-1630.
17. Nangaku M Chronic hypoxia and tubulointerstitial injury: A final common pathway to end-stage renal failure. J Am Soc Nephrol 2006, 17:17-25.
18. Krolewski AS, Laffel LM, Krolewski M, et al. Glycosylated hemoglobin and the risk of microalbuminuria in patients with insulin-dependent diabetes mellitus. N Engl J Med 1995, 332:1251-1255.
19. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993, 329:977-986.
20. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005, 353:2643-2653.
21. Fioretto P, Steffes MW, Sutherland DE, et al. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 1998, 339:69-75.
22. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998, 352:837-853.
23. Brownlee M Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414:813-820.
24. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358:2560-2572.
25. Brownlee M The pathobiology of diabetic complications: A unifying mechanism. Diabetes 2005, 54:1615-1625.
26. Bohlender JM, Franke S, Stein G, Wolf G Advanced glycation end products and the kidney. Am J Physiol Renal Physiol 2005, 289:F645-F659.
27. Rüster C, Bondeva T, Franke S, et al. Angiotensin II upregulates RAGE expression on podocytes: Role of AT2 receptors. Am J Nephrol 2009, 29:538-550.
28. Ribeiro-Oliveira A, Nogueira AI, Pereira RM, et al. The renin-angiotensin system and diabetes: An update. Vasc Health Risk Manag 2008, 4:787-803.
29. Wolf G Renal injury due to renin-angiotensin-aldosterone system activation of the transforming growth factor-beta pathway. Kidney Int 2006, 70:1914-1999.
30. Toma I, Kang JJ, Sipos A, et al. Succinate receptor GPR91 provides a direct link between high glucose levels and renin release in murine and rabbit kidney. J Clin Invest 2008, 118:2526-2534.
31. Nguyen G, Danser AH Prorenin and (pro)renin receptor: A review of available data from in vitro studies and experimental models in rodents. Exp Physiol 2008, 93:557-563.
32. Huang XR, Chen WY, Truong LD, Lan HY Chymase is upregulated in diabetic nephropathy: Implications for an alternative pathway of angiotensin II-mediated diabetic renal and vascular disease. J Am Soc Nephrol 2003, 14:1738-1747.
33. Johnson RJ, Perez-Pozo SE, Sautin YY, et al. Hypothesis: Could excessive fructose intake and uric acid cause type 2 diabetes?. Endocr Rev 2009, 30:96-116.
34. Hovind P, Rossing P, Tarnow L, et al. Serum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetes-an inception cohort study. Diabetes 2009, 58:1668-1671.
35. Hasslacher C, Ritz E, Wahl P, Michael C Similar risks of nephropathy in patients with type I or type II diabetes mellitus. Nephrol Dial Transplant 1989, 4:859-863.
36. Parving HH, Lewis JB, Ravid M, et al. DEMAND investigators: Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: A global perspective. Kidney Int 2006, 69:2057-2063.
37. So WY, Ma RC, Ozaki R, et al. Angiotensin-converting enzyme (ACE) inhibition in type 2, diabetic patients-interaction with ACE insertion/deletion polymorphism. Kidney Int 2006, 69:1438-1443.
38. Whaley-Connell A, Sowers JR, McCullough PA, et al. Diabetes mellitus and CKD awareness: The Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES). Am J Kidney Dis 2009, 4(Suppl 1):S11-S21.
39. King H, Aubert RE, Herman WH Global burden of diabetes, 1995-2025: Prevalence, numerical estimates, and projections. Diabetes Care 1998, 21:1414-1431.
40. Nguyen NT, Magno CP, Lane KT, et al. Association of hypertension, diabetes, dyslipidemia, and metabolic syndrome with obesity: Findings from the National Health and Nutrition Examination Survey, 1999 to 2004. J Am Coll Surg 2008, 207:928-934.
41. Wolf G After all those fat years: Renal consequences of obesity. Nephrol Dial Transplant 2003, 18:2471-2474.
42. Chagnac A, Herman M, Zingerman B, et al. Obesity-induced glomerular hyperfiltration: Its involvement in the pathogenesis of tubular sodium reabsorption. Nephrol Dial Transplant 2008, 23:3946-3952.
43. Rasouli N, Kern PA Adipocytokines and the metabolic complications of obesity. J Clin Endocrinol Metab 2008, 93(Suppl 1):S64-S73.
44. Mogensen CE How to protect the kidney in diabetic patients with special reference to NIDDM. Diabetes 1997, 56(Suppl 2):104-111.
45. Mourad JJ, Le Jeune S Blood pressure control, risk factors and cardiovascular prognosis in patients with diabetes: 30 years of progress. J Hypertens 2008, 26:S7-S13.
46. Muxfeldt ES, Cardoso CR, Salles GF Prognostic value of nocturnal blood pressure reduction in resistant hypertension. Arch Intern Med 2009, 169:874-880.
47. Winer N, Sowers JR Diabetes and arterial stiffening. Adv Cardiol 2007, 44:245-251.
48. Girach A, Vignati L Diabetic microvascular complications-can the presence of one predict the development of another?. J Diabetes Complications 2006, 20:228-237.
49. Wolf G, Müller N, Mandecka A, Müller UA Association of diabetic retinopathy and renal function in patients with types 1 and 2 diabetes mellitus. Clin Nephrol 2007, 68:81-86.
50. Margolis DJ, Hofstad O, Feldman HI Association between renal failure and foot ulcer of lower-extremity amputation in patients with diabetes. Diabetes Care 2008, 31:1331-1336.
51. Knudsen ST, Laugesen E, Hansen KW, et al. Ambulatory pulse pressure, decreased nocturnal blood pressure reduction and progression of nephropathy in type 2 diabetic patients. Diabetologia 2009, 52:698-704.
52. Krentz AJ, Clough G, Byrne CD Interactions between microvascular and macrovascular disease in diabetes: Pathophysiology and therapeutic implications. Diabetes Obes Metab 2007, 9:781-791.
53. Gall MA, Borch-Johnsen K, Hougaard P, et al. Albuminuria and poor glycemic control predict mortality in NIDDM. Diabetes 1995, 44:1303-1309.
54. Brantsma AH, Bakker SJ, de Zeeuw D, et al. PREVEND Study Group: Extended prognostic value of urinary albumin excretion for cardiovascular events. J Am Soc Nephrol 2008, 19:1785-1791.
55. Wolf G, Müller N, Busch M, et al. Diabetic foot syndrome and renal function in type 1 and 2 diabetes mellitus show close association. Nephrol Dial Transplant 2009, 24:1896-1901.
56. Fioretto P, Mauer M, Brocco E, et al. Patterns of renal injury in NIDDM patients with microalbuminuria. Diabetologia 1996, 39:1569-1576.
57. Fioretto P, Steffes MW, Sutherland DE, Mauer M Sequential renal biopsies in insulin-dependent diabetic patients: Structural factors associated with clinical progression. Kidney Int 1995, 48:1929-1935.
58. Wolf G, Chen S, Ziyadeh FN From the periphery of the glomerular capillary wall toward the center of disease: Podocyte injury comes of age in diabetic nephropathy. Diabetes 2005, 54:1626-1634.
59. Marshall SM The podocyte: A major player in the development of diabetic nephropathy. Horm Metab Res 2005, 37(Suppl 1):9-16.
60. Pagtalunan ME, Miller PL, Jumping-Eagle S, et al. Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest 1997, 99:342-348.
61. Ziyadeh FN Significance of tubulointerstitial changes in diabetic renal disease. Kidney Int 1996, 54:S10-S13.
62. Musso C, Javor E, Cochran E, et al. Spectrum of renal diseases associated with extreme forms of insulin resistance. Clin J Am Soc Nephrol 2006, 1:616-622.
63. Redon J Measurement of microalbuminuria-what the nephrologist should know. Nephrol Dial Transplant 2006, 21:573-576.
64. Akimoto T, Ito C, Saito O, et al. Microscopic hematuria and diabetic glomerulosclerosis-clinicopathological analysis of type 2 diabetic patients associated with overt proteinuria. Nephron Clin Pract 2008, 109-c119.
65. Pham TT, Sim JJ, Kujubu DA, et al. Prevalence of nondiabetic renal disease in diabetic patients. Am J Nephrol 2007, 27:322-328.